Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner
- Recognition from Ernst & Young validates company's leadership and growth trajectory
- Company's proprietary BioREtain technology demonstrates innovation in wound care solutions
- FDA registered and AATB accredited manufacturing facility in Pompano Beach
- Expanding portfolio of wound care products with nationwide clinical adoption
- None.
Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies
POMPANO BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US has celebrated ambitious entrepreneurs who are transforming industries, impacting communities and creating long-term value.
Mr. Matuszewski was chosen by an independent panel of past winners, top CEOs, private equity and venture capital investors and business leaders. Judges assessed candidates on long-term value creation, entrepreneurial spirit, purpose-driven commitment and significant growth and impact.
Jason Matuszewski, CEO of BioStem Technologies, commented: “I’m deeply honored to be named an Entrepreneur Of The Year® 2025 Florida Award winner. This recognition from EY is a reflection of the tireless dedication of the entire BioStem team, whose work is rooted in innovation and driven by a shared mission to improve the lives of patients suffering from chronic, non-healing wounds. Our journey has been powered by science, purpose, and a steadfast belief in the potential of regenerative medicine to transform care and deliver meaningful outcomes for patients in need,” Stated Mr. Matuszewski. “I’m especially grateful to my co-founder and COO, Andrew VanVurst, whose operational leadership and mission-first mindset have guided BioStem from its earliest days to where we are today - a high-growth company at the forefront of innovation and operational excellence with aspirations to support patients across the continuum of care. This award is not just a personal milestone - it represents the collective vision, discipline, and heart of our entire team at The STEM. We remain committed to advancing our platform, expanding our impact, and making a lasting difference in the healthcare system and the communities we serve.”
Headquartered in Pompano Beach, Florida, BioStem Technologies is a leading MedTech company dedicated to improving the lives of patients with chronic, non-healing wounds. The company develops and manufactures placental-derived allografts using its proprietary BioREtain® technology, designed to preserve the tissue’s native properties and optimize clinical outcomes. BioStem’s expanding portfolio is used by clinicians across the country to meet the growing demand for advanced wound care solutions. The company is committed to scientific excellence, operational integrity, and delivering meaningful value to patients, providers, and the broader healthcare system.
As a Florida award winner, Mr. Matuszewski is now eligible for consideration for the Entrepreneur Of The Year 2025 National Awards. The National Award winners, including the Entrepreneur Of The Year National Overall Award winner, will be announced in November at the Strategic Growth Forum®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies. The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the EY World Entrepreneur Of The Year™ Award in June 2026.
Entrepreneur Of The Year recognizes many different types of business leaders for their ingenuity, courage and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to strengthen it for the future.
The Entrepreneur Of The Year program has recognized the leadership of entrepreneurs such as:
|
|
Sponsors:
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, LLC, Marsh USA, and SAP.
About Entrepreneur Of The Year:
Founded in 1986, Entrepreneur Of The Year has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries globally.
The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the EY World Entrepreneur Of The Year™ competition. Visit ey.com/us/eoy.
About EY:
EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.
Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.
EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.
All in to shape the future with confidence.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.
Join BioStem’s Distribution List & Social Media:
To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure.
BioStem’s quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (“AATB”) and adhere to Good Tissue Practices (cGTP and Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Investor Relations:
Adam Holdsworth
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
Note Regarding Forward-Looking Statements:
Except for statements of historical fact, this press release also contains forward-looking statements. These forward-looking statements relate to expectations or forecasts of future events, including with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, among other things, statements regarding the Company’s: ability to clear all current SEC comments; expectations regarding filing an amended Form 10, including the timeframe therefor and the content therein; and expectations regarding the Company’s plan and ability to satisfy Nasdaq listing requirements. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from the expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the risk that the Company may be unable to list its stock on Nasdaq or maintain compliance with Nasdaq’s continued listing standards; the impact of any changes to the accounting treatment of the Company’s revenue and expenses; the risk of receiving additional comments from the SEC; the competition that the Company faces, which could adversely affect its business, results of operations and financial condition; the risk of rapid technological change, which could cause the Company’s products to become obsolete or cause the Company to become unable to effectively compete; the risk that the Company is unable to successfully market its products to the end users of such products; the risk that the Company may be unable to raise funds to expand its business; changes in applicable laws or regulations; and the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is BioStem Technologies (BSEM) main business focus?
What products are in BioStem Technologies' (BSEM) portfolio?
What recognition did BSEM's CEO receive from Ernst & Young in 2025?
What certifications does BioStem Technologies' manufacturing facility have?
What is BioStem Technologies' BioREtain technology?
